scholarly journals Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen

2019 ◽  
Vol 29 (4) ◽  
pp. 300-302 ◽  
Author(s):  
I García-Gutiérrez ◽  
M Acevedo ◽  
P Tornero ◽  
A Matilla ◽  
L Márquez ◽  
...  
1991 ◽  
Vol 65 (05) ◽  
pp. 635-635 ◽  
Author(s):  
Claude Juhan ◽  
Serge Haupert ◽  
Gilles Miltgen ◽  
Nadine Girard ◽  
Pierre Dulac

Pharmacology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Pavla Pokorná ◽  
Martin Šíma ◽  
Birgit Koch ◽  
Dick Tibboel ◽  
Ondřej Slanař

<b><i>Introduction:</i></b> Sufentanil is a potent synthetic opioid used for analgesia in neonates; however, data concerning drug disposition of sufentanil and dosage regimen are sparse in this population. Therefore, the aim of the study was to explore sufentanil disposition and to propose optimal loading and maintenance doses of sufentanil in ventilated full-term neonates. <b><i>Methods:</i></b> Individual sufentanil pharmacokinetic parameters were calculated based on therapeutic drug monitoring data using a 2-compartmental model. Linear regression models were used to explore the covariates. <b><i>Results:</i></b> The median (IQR) central volume of distribution (Vd<sub>c</sub>) and clearance (CL) for sufentanil were 4.7 (4.1–5.4) L/kg and 0.651 (0.433–0.751) L/h/kg, respectively. Linear regression models showed relationship between Vd<sub>c</sub> (L) and GA (<i>r</i><sup>2</sup> = 0.3436; <i>p</i> = 0.0452) as well as BW (<i>r</i><sup>2</sup> = 0.4019; <i>p</i> = 0.0268). Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78–2.48) μg/kg and 0.29 (95% CI: 0.22–0.37) μg/kg/h, respectively. Median daily COMFORT-B (IQR) scores ranged from 6 to 23 while no significant relationship between pharmacokinetic parameters and COMFORT-B scores was found. <b><i>Discussion/Conclusion:</i></b> Body weight and gestational age were found as weak covariates for sufentanil distribution, and the dosage regimen was developed for a prospective trial.


1989 ◽  
Vol 13 (4) ◽  
pp. 325-329
Author(s):  
R. K. Chaudhary ◽  
A. K. Srivastava
Keyword(s):  

1976 ◽  
Vol 10 (10) ◽  
pp. 898-898
Author(s):  
M Bardare ◽  
G U Cislaghi ◽  
M Mandelli ◽  
F Sereni

1977 ◽  
Vol 15 (23) ◽  
pp. 92-92

Depressed patients tend to be forgetful, and for them a simple dosage regimen is particularly appropriate. The use of a single daily dosage depends on the drug having a relatively long (over 36 hours) half-life in the body and being tolerated in a single large dose. Many tricyclic anti-depressives fulfil these requirements provided that the single dose is given before the patient goes to bed. Unwanted effects such as dry mouth and blurred vision, which are troublesome during the day, are not a problem during sleep. The sedative actions of many of these drugs can help the insomniac depressed patient who might otherwise need a separate hypnotic.


PEDIATRICS ◽  
1988 ◽  
Vol 82 (4) ◽  
pp. 675-676
Author(s):  
JEFFREY BRENT ◽  
BARRY H. RUMACK ◽  
KENNETH W. KULIG

To the Editor.— The current (11th) edition of the Harriet Lane Handbook contains several serious errors we wish to bring to your attention. These are (1) an incorrect and inadequate 24-hour oral dosage regimen for which there is no scientific basis, (2) a dangerous recommendation for administering oral Mucomyst intravenously, (3) a suboptimal intravenous dosage regimen, (4) the erroneous assertion that N-acetylcysteine (NAC or Mucomyst) therapy is ineffective if initiated longer than ten hours postingestion, and (5) an incorrectly adapted nomogram for determining acetaminophen toxicity.


1996 ◽  
Vol &NA; (1032) ◽  
pp. 8
Author(s):  
&NA;
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document